文献速递胸部肿瘤

一种用于预测NSCLC中程序性细胞死亡蛋白或配体-1抑制免疫治疗疗效与肺毒性的新型放射基因组生物标志物

A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
PubMed 文献 · J Thorac Oncol · 2023-02-10

本研究为回顾性研究,共纳入340例患者中194例CT扫描合格者,利用85例增强胸部CT的影像组学特征与CD274表达构建复合影像组学标签LCI-RPV,并在两个独立测试队列(66例和43例)中验证。LCI-RPV可预测PD-L1阳性、高PD-L1表达、3个月客观缓解及肺炎发生,并可将患者分层为高、低风险生存组。

要点

  • LCI-RPV在两个NSCLC测试队列中预测PD-L1阳性,AUC分别为0.70(95%CI 0.57-0.84)和0.70(95%CI 0.46-0.94)。
  • 在一个队列中,LCI-RPV预测PD-L1>50%的AUC为0.72(95%CI 0.59-0.85),>90%的AUC为0.66(95%CI 0.45-0.88)。
  • LCI-RPV预测3个月客观缓解AUC为0.68(95%CI 0.52-0.85),预测肺炎发生AUC为0.64(95%CI 0.48-0.80)。

核心结论

  • 基于反应向量CD274开发的CT影像组学标签有助于评估NSCLC患者是否适合接受PD-1或PD-L1检查点抑制剂免疫治疗。

研究设计与样本

  • 回顾性研究,共194例患者具有合格CT扫描(来自340例患者),发现集为85例增强胸部CT,以CD274计数为反应向量开发复合影像组学标签LCI-RPV。
  • 在两个独立测试队列中验证,分别为66例和43例接受PD-1或PD-L1抑制免疫治疗的NSCLC患者。

主要发现

  • LCI-RPV在两个NSCLC测试队列中预测PD-L1阳性,AUC分别为0.70(95%CI 0.57-0.84)和0.70(95%CI 0.46-0.94)。
  • 在一个队列中,LCI-RPV预测PD-L1表达>50%的AUC为0.72(95%CI 0.59-0.85),预测>90%的AUC为0.66(95%CI 0.45-0.88)。
  • 在同一队列中,LCI-RPV预测3个月肿瘤客观缓解的AUC为0.68(95%CI 0.52-0.85),预测肺炎发生的AUC为0.64(95%CI 0.48-0.80)。
  • LCI-RPV将患者显著分层为高、低风险生存组,风险比分别为2.26(95%CI 1.21-4.24,p=0.011)和2.45(95%CI 1.07-5.65,p=0.035)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patient selection for checkpoint inhibitor immunotherapy is currently guided by programmed death-ligand 1 (PD-L1) expression obtained from immunohistochemical staining of tumor tissue samples. This approach is susceptible to limitations resulting from the dynamic and heterogeneous nature of cancer cells and the invasiveness of the tissue sampling procedure. To address these challenges, we developed a novel computed tomography (CT) radiomic-based signature for predicting disease response in patients with NSCLC undergoing programmed cell death protein 1 (PD-1) or PD-L1 checkpoint inhibitor immunotherapy. METHODS: This retrospective study comprises a total of 194 patients with suitable CT scans out of 340. Using the radiomic features computed from segmented tumors on a discovery set of 85 contrast-enhanced chest CTs of patients diagnosed with having NSCLC and their CD274 count, RNA expression of the protein-encoding gene for PD-L1, as the response vector, we developed a composite radiomic signature, lung cancer immunotherapy-radiomics prediction vector (LCI-RPV). This was validated in two independent testing cohorts of 66 and 43 patients with NSCLC treated with PD-1 or PD-L1 inhibition immunotherapy, respectively. RESULTS: LCI-RPV predicted PD-L1 positivity in both NSCLC testing cohorts (area under the curve [AUC] = 0.70, 95% confidence interval [CI]: 0.57-0.84 and AUC = 0.70, 95% CI: 0.46-0.94). In one cohort, it also demonstrated good prediction of cases with high PD-L1 expression exceeding key treatment thresholds (>50%: AUC = 0.72, 95% CI: 0.59-0.85 and >90%: AUC = 0.66, 95% CI: 0.45-0.88), the tumor's objective response to treatment at 3 months (AUC = 0.68, 95% CI: 0.52-0.85), and pneumonitis occurrence (AUC = 0.64, 95% CI: 0.48-0.80). LCI-RPV achieved statistically significant stratification of the patients into a high- and low-risk survival group (hazard ratio = 2.26, 95% CI: 1.21-4.24, p = 0.011 and hazard ratio = 2.45, 95% CI: 1.07-5.65, p = 0.035). CONCLUSIONS: A CT radiomics-based signature developed from response vector CD274 can aid in evaluating patients' suitability for PD-1 or PD-L1 checkpoint inhibitor immunotherapy in NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Chen M, Lu H, Copley SJ, et al. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. J Thorac Oncol. 2023. PMID: 36773776. doi:10.1016/j.jtho.2023.01.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。